An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
Completed · Phase 2
Conditions studied: Malignant Solid Tumor
In brief
The study objective of this open label, multicenter study is to provide access to NKTR-102 treatment to subjects previously enrolled in a NKTR-102 study who are without signs of disease progression since receiving NKTR-102. In addition the study will evaluate the safety of continued exposure to NKTR-102, observe disease status and survival status in subjects receiving NKTR-102, and evaluate the efficacy of NKTR-102 in subjects with advanced or metastatic solid tumors.
Key facts
- Study ID
- NCT01457118
- Run by
- Nektar Therapeutics
- People needed
- 27
- Starts
- 2011-10-01
- Expected to finish
- 2017-11-01
- Last updated by the study team
- 2021-07-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Investigator Site - Los Angeles — Los Angeles, California, United States
- Investigator Site - San Francisco — San Francisco, California, United States
- Investigator Site - Whittier — Whittier, California, United States
- Investigator Site - Minneapolis — Minneapolis, Minnesota, United States
- Investigator Site - Cleveland — Cleveland, Ohio, United States
- Investigator Site - Bruxelles — Brussels, Belgium
- Investigator Site - Liege — Liège, Belgium
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.